Elan Corporation PLC, Eisai Company, Ltd. to Pay $214 Million to U.S. to Resolve Allegations of Illegal Promotion of Epilepsy Drug Zonegran

Wall Street Journal -- The U.S. arms of drug companies Elan Corp. and Eisai Co. will pay $214 million to resolve allegations that they illegally promoted the epilepsy drug Zonegran, the U.S. Justice Department said Wednesday. Elan, of Dublin, Ireland, will pay $203 million, the bulk of the settlement. The company's U.S. subsidiary, Elan Pharmaceuticals Inc., has agreed to plead guilty to a misdemeanor criminal charge of misbranding the drug.

Back to news